Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr 21:2021:5524566.
doi: 10.1155/2021/5524566. eCollection 2021.

Increased Circulatory Interleukin-17A Levels in Patients with Progressive and Leukotrichial Vitiligo

Affiliations

Increased Circulatory Interleukin-17A Levels in Patients with Progressive and Leukotrichial Vitiligo

Thai Van Thanh Le et al. Dermatol Res Pract. .

Abstract

Background: Vitiligo is a chronic condition characterized by skin depigmentation. Although not life-threatening, it significantly impacts quality of life. The pathophysiology of vitiligo remains poorly understood, and treatment options are limited. Mounting evidence supports the importance of autoreactive T cells and, particularly interleukin-17A- (IL-17A-) secreting Th17 cells, in vitiligo. IL-17A targeting has been proven successful in various inflammatory dermatological conditions, including psoriasis and lupus erythematosus.

Objective: We evaluated the relationship between serum levels of IL-17A and the clinicopathological characteristics of Vietnamese vitiligo patients.

Methods: In this cross-sectional study, we analyzed data from 52 nonsegmental vitiligo patients and 50 age- and sex-matched healthy individuals. Serum levels of IL-17A were measured using an enzyme-linked immunosorbent assay. We evaluated the correlation between IL-17A levels and clinical characteristics including leukotrichia, disease duration, vitiligo activity, and body surface area involvement.

Results: Patients with progressive vitiligo had significantly higher IL-17A levels than patients with stable vitiligo (P = 0.014) or healthy individuals (P = 0.002). In addition, serum IL-17A levels were higher in vitiligo patients with leukotrichia than in patients without it (P = 0.04). Furthermore, serum IL-17A levels were negatively correlated with age (r = -0.39, P = 0.004) and age of onset (r = -0.33, P = 0.016) in vitiligo patients.

Conclusions: Higher serum levels of IL-17A in patients with progressive vitiligo and leukotrichia suggest a potential role of IL-17A in melanocyte destruction in the epidermis and the follicular matrix.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there are no conflicts of interest.

Figures

Figure 1
Figure 1
Serum levels of IL-17A in active and stable disease and healthy controls.
Figure 2
Figure 2
The correlations of serum IL-17A levels with age (a) and age of onset (b) in vitiligo patients.

Similar articles

Cited by

References

    1. Alikhan A., Felsten L. M., Daly M., Petronic-Rosic V. Vitiligo: a comprehensive overview. Journal of the American Academy of Dermatology. 2011;65(3):473–491. doi: 10.1016/j.jaad.2010.11.061. - DOI - PubMed
    1. Alkhateeb A., Fain P. R., Thody A., Bennett D. C., Spritz R. A. Epidemiology of vitiligo and associated autoimmune diseases in Caucasian probands and their families. Pigment Cell Research. 2003;16(3):208–214. doi: 10.1034/j.1600-0749.2003.00032.x. - DOI - PubMed
    1. Krüger C., Schallreuter K. U. A review of the worldwide prevalence of vitiligo in children/adolescents and adults. International Journal of Dermatology. 2012;51(10):1206–1212. doi: 10.1111/j.1365-4632.2011.05377.x. - DOI - PubMed
    1. Boissy R. E., Manga P. On the etiology of contact/occupational vitiligo. Pigment Cell Research. 2004;17(3):208–214. doi: 10.1111/j.1600-0749.2004.00130.x. - DOI - PubMed
    1. Cucchi M. L., Frattini P., Santagostino G., Orecchia G. Higher plasma catecholamine and metabolite levels in the early phase of nonsegmental vitiligo. Pigment Cell Research. 2000;13(1):28–32. doi: 10.1034/j.1600-0749.2000.130106.x. - DOI - PubMed